AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Biodesix, Inc.
Video analysis: BDSX
All videosNo video analysis for this stock yet. Request one from our team.
News: BDSX
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the
Biodesix to Participate in Upcoming Investor Conferences
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?
Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference
Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy.
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?
Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
